| Trial ID # | NCT02606305; FORWARD II-2 |
| Phase | Ib/II |
| Drug Class | Antibody Drug Conjugates: FRalpha |
| Drug Name | Mirvetuximab soravtansine |
| Alternate Drug Names | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate |
| Drugs in Trial | Bevacizumab, Mirvetuximab soravtansine |
| Eligible Participant | Platinum sensitive FRalpha+ ovarian cancer; IHC: ≥ 25% tumor cells at ≥ 2+ intensity |
| Patients Enrolled | 31 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DoR, PFS, evaluated per RECIST |
| Biomarkers | Exploratory analysis: FRalpha high (IHC: ≥ 75% tumor cells at ≥ 2+ intensity) |
| Efficacy | ORR: 48% Exploratory analysis, FRalpha high (n=16): |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of mirvetuximab soravtansine with bevacizumab demonstrates an encouraging ORR in platinum sensitive patients with high FRalpha expression |
| Reference | O'Malley DM et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. J Clin Oncol (2021) 39 (suppl 15; abstr 5504) O'Malley DM et al. Mirvetuximab Soravtansine and Bevacizumab in Folate Receptor Alpha-Positive Ovarian Cancer: Efficacy in Patients With and Without Prior Bevacizumab. IGCS 2022, presentation |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.